E-DRUG: FDA announces withdrawal of anti-obesity drugs (2)
----------------------------------------------------------
High time. These were drugs which had no business being given
marketing approval in the first place.
Besides the cardiac and pulmonary hypertension risks, there is also
evidence of neurotoxicity.
[1] JAMA 1997 Aug 27;278(8):666-672
Brain serotonin neurotoxicity and primary pulmonary hypertension
from fenfluramine and dexfenfluramine. A systematic review of the
evidence.
McCann UD, Seiden LS, Rubin LJ, Ricaurte GA
[2] Br J Pharmacol 1997 Jul;121(5):889-900
In vivo evidence for free radical involvement in the degeneration
of rat brain 5-HT following administration of MDMA ('ecstasy') and
p-chloroamphetamine but not the degeneration following fenfluramine.
Colado MI, O'Shea E, Granados R, Murray TK, Green AR
[3] J Pharmacol Exp Ther 1997 Jun;281(3):1487-1498
Selective serotonin reuptake inhibitors dissociate fenfluramine's
anorectic and neurotoxic effects: importance of dose, species and
drug.
McCann UD, Yuan J, Hatzidimitriou G, Ricaurte GA
[4] Synapse 1997 May;26(1):36-45
Combined phentermine/fenfluramine administration enhances depletion
of serotonin from central terminal fields.
Lew R, Weisenberg B, Vosmer G, Seiden LS
[5] J Pharmacol Exp Ther 1994 May;269(2):792-798
Dexfenfluramine and serotonin neurotoxicity: further preclinical
evidence that clinical caution is indicated.
McCann U, Hatzidimitriou G, Ridenour A, Fischer C, Yuan J, Katz J,
Ricaurte G